LT2970291T - Vaisto paruošimo technologiniai procesai ir tarpiniai junginiai - Google Patents

Vaisto paruošimo technologiniai procesai ir tarpiniai junginiai

Info

Publication number
LT2970291T
LT2970291T LTEPPCT/EP2014/054621T LT14054621T LT2970291T LT 2970291 T LT2970291 T LT 2970291T LT 14054621 T LT14054621 T LT 14054621T LT 2970291 T LT2970291 T LT 2970291T
Authority
LT
Lithuania
Prior art keywords
intermediates
medicament
preparing
processes
Prior art date
Application number
LTEPPCT/EP2014/054621T
Other languages
English (en)
Inventor
Philip Pye
Cyril BEN HAIM
Matteo CONZA
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica, N.V. filed Critical Janssen Pharmaceutica, N.V.
Publication of LT2970291T publication Critical patent/LT2970291T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
LTEPPCT/EP2014/054621T 2013-03-15 2014-03-11 Vaisto paruošimo technologiniai procesai ir tarpiniai junginiai LT2970291T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17
PCT/EP2014/054621 WO2014139970A1 (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Publications (1)

Publication Number Publication Date
LT2970291T true LT2970291T (lt) 2022-06-10

Family

ID=51535892

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2014/054621T LT2970291T (lt) 2013-03-15 2014-03-11 Vaisto paruošimo technologiniai procesai ir tarpiniai junginiai

Country Status (19)

Country Link
EP (1) EP2970291B1 (lt)
JP (1) JP6777398B2 (lt)
KR (2) KR102377688B1 (lt)
CN (2) CN105026400A (lt)
AU (2) AU2014230935A1 (lt)
BR (1) BR112015021856A2 (lt)
CA (1) CA2901510C (lt)
DK (1) DK2970291T3 (lt)
EA (1) EA201591685A1 (lt)
ES (1) ES2924193T3 (lt)
HR (1) HRP20220628T1 (lt)
HU (1) HUE058914T2 (lt)
LT (1) LT2970291T (lt)
MX (2) MX2015012731A (lt)
MY (1) MY194905A (lt)
PE (1) PE20151652A1 (lt)
SG (2) SG10201809696UA (lt)
SI (1) SI2970291T1 (lt)
WO (1) WO2014139970A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014004971B1 (pt) 2011-09-02 2021-02-09 Incyte Holdings Corporation compostos heterociclilaminas, sua composição farmacêutica e seus usos
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
SI3831833T1 (sl) * 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
LV15201B (lv) * 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
EP3661939B1 (en) * 2017-08-01 2021-07-21 Boehringer Ingelheim International GmbH Intermediate compounds and methods
MX2021014245A (es) 2019-05-21 2022-01-06 Janssen Pharmaceutica Nv Procedimientos y productos intermedios para preparar un inhibidor de btk.
KR20220011668A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212327T3 (da) * 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
KR101315610B1 (ko) * 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA2874756C (en) * 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
SI2414363T1 (sl) 2009-03-31 2014-04-30 Boehringer Ingelheim Gmbh Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
AU2011276955B2 (en) * 2010-07-09 2014-11-06 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
EP2632898A4 (en) * 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
KR20140048968A (ko) * 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
US20150291554A1 (en) * 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
JP2016510779A (ja) 2016-04-11
KR20210123429A (ko) 2021-10-13
MX2015012731A (es) 2016-02-18
HUE058914T2 (hu) 2022-09-28
CN112608298A (zh) 2021-04-06
AU2018204086A1 (en) 2018-06-28
CN105026400A (zh) 2015-11-04
EA201591685A1 (ru) 2016-01-29
WO2014139970A1 (en) 2014-09-18
AU2018204086B2 (en) 2020-03-12
MY194905A (en) 2022-12-22
MX2020012596A (es) 2021-02-09
PE20151652A1 (es) 2015-11-12
BR112015021856A2 (pt) 2017-07-18
JP6777398B2 (ja) 2020-10-28
AU2014230935A1 (en) 2015-09-03
DK2970291T3 (da) 2022-08-01
KR102377688B1 (ko) 2022-03-22
EP2970291A1 (en) 2016-01-20
KR102311329B1 (ko) 2021-10-14
EP2970291B1 (en) 2022-05-11
SI2970291T1 (sl) 2022-07-29
SG11201507595XA (en) 2015-10-29
KR20150132172A (ko) 2015-11-25
CA2901510A1 (en) 2014-09-18
ES2924193T3 (es) 2022-10-05
CA2901510C (en) 2022-11-29
HRP20220628T1 (hr) 2022-06-24
SG10201809696UA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
KR102377688B1 (ko) 약제를 제조하기 위한 방법 및 중간체
IL245211A0 (en) an inhaler for the medicine
AU351520S (en) Inhaler
AU352076S (en) Inhaler
LT3019225T (lt) Inhaliatorius
GB2585796B (en) A patient interface
PT3632373T (pt) Inalador
HUE053417T2 (hu) Inhalátor
GB2530229B (en) A splint
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
GB201313835D0 (en) A medicament
HRP20181933T1 (hr) Farmaceutski postupak i intermedijari
HK1216178A1 (zh) 用於製備藥物的方法和中間體
GB201320786D0 (en) Medicament
GB201311546D0 (en) A bandage
GB201305071D0 (en) A wheelchair
AU348321S (en) A wheelchair